Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis...

CORT : 51.40 (+0.49%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).He will assume his new role on Dec....

BEAM : 29.01 (+8.04%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen (STK-001), for the treatment of Dravet syndrome, a severe...

IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
STOK : 11.68 (+3.36%)
SPRO : 0.9551 (-4.30%)
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug

Rezolute, Inc. RZLT announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead pipeline candidate, ersodetug (RZ358), for the treatment of hypoglycemia caused by tumor hyperinsulinism...

IMCR : 28.33 (-0.33%)
RZLT : 4.39 (+3.78%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study

Senti Biosciences, Inc. SNTI announced positive initial data from a phase I study that evaluated its chimeric antigen receptor natural killer (CAR-NK) cell therapy candidate, SENTI-202, for the treatment...

IMCR : 28.33 (-0.33%)
SNTI : 3.97 (-0.25%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Immunocore Secures NHS Reimbursement for KIMMTRAK in England for Uveal Melanoma Treatment

Immunocore's KIMMTRAK receives NHS funding for HLA-A*02:01-positive adults with metastatic uveal melanoma after NICE's recent recommendation.Quiver AI SummaryImmunocore has announced that KIMMTRAK (tebentafusp)...

IMCR : 28.33 (-0.33%)
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Esperion Therapeutics, Inc. ESPR announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as a...

ESPR : 2.19 (+0.69%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Altimmune Stock Up More Than 25% in a Month: Here's Why

Altimmune ALT is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis...

IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
ALT : 8.25 (+0.86%)
SPRO : 0.9551 (-4.30%)
Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally...

IMCR : 28.33 (-0.33%)
MIRM : 41.51 (+0.92%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Corcept Shares Rise More Than 60% in Three Months: Here's Why

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s sole-marketed drug, Korlym (mifepristone), which is...

CORT : 51.40 (+0.49%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar